

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN ATACICEPT
 PRONUNCIATION a ta' ki sept
 THERAPEUTIC CLAIM Treatment of autoimmune diseases

CHEMICAL NAME

Human Transmembrane Activator and CAML Interactor (TACI) – Immunoglobulin G₁ Fc Domain Fusion Protein (Fc5)

STRUCTURAL FORMULA

AMRSCPEEQY	WDPLLGTCMS	CKTICNHQSQ	RTCAAFCRSL	SCRKEQGKFY
DHLLRDCISC	ASICGQHPKQ	CAYFCENKLR	SEPKSSDKTH	<u>T</u> <u>C</u> PP <u>C</u> PAPEA
EGAPSVFLFP	PKPKDTLMIS	RTPEVTCVVV	DVSHEDPEVK	FNWYVDGVEV
HNAKTKPREE	<u>QY</u> <u>N</u> STYRVVS	VLTVLHQDWL	NGKEYKCKVS	NKALPSSIEK
TISKAKGQPR	EPQVYTLPPS	RDELTKNQVS	LTCLVKGFYP	SDIAVEWESN
GQPENNYKTT	PPVLDSGGSF	FLYSKLTVDK	SRWQQGNVFS	CSVMHEALHN
HYTQKSLSLS	PGK			

1-81-TACI (human) fusion protein with 82-313-modified immunoglobulin G₁ (human γ 1-chain Fc fragment), dimer. Monomers are covalently linked by disulphide bridges at cysteines 92 and 95 of each monomer (underlined). A potentially glycosylated asparagines-residue (underlined, bold) is indicated.

MOLECULAR FORMULA C₃₁₀₄H₄₇₈₈N₈₅₆O₉₅₀S₄₄ (homodimer)
 MOLECULAR WEIGHT 73.4 kDa
 CODE TACI-Fc5
 TRADEMARK None as yet
 MANUFACTURER Merck Serono, a division of Merck KGaA, Darmstadt, Germany
CAS REGISTRY NUMBER 845264-92-8